In a significant analysis and discussion on oncogenic role of DNMT3A in AML, Chen et al. (2022) revealed that CEBPA interacted with DNMT3A N terminus (a required structure for normal development and DNA methylation at DNMT3A1-enriched regions) (Gu et al., 2022), preventing DNMT3A from binding DNA and catalyzing CpG methylation. This evidence concerns the gene CEBPA and acute myeloid leukemia.